A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease

Summary

This study is designed to evaluate treatment effects of ATH-1017 (fosgonimeton) in mild to moderate Alzheimer's subjects with a randomized treatment duration of 26-weeks.

Timeline

Start

2020-11-23

Primary completion

2022-05-20

Completion

2022-05-20

Outcome

Missed primary endpoint

release “topline results from the ACT-AD trial in Alzheimer’s disease. While the primary endpoint did not reach statistical significance” leonabio.com ↗

Publications

• Background McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):263-9. doi: 10.1016/j.jalz.2011.03.005. Epub 2011 Apr 21.

Drugs

Indications